Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Neurooncol Adv ; 6(1): vdae041, 2024.
Article in English | MEDLINE | ID: mdl-38596716

ABSTRACT

Background: Liquid biopsy based on circulating tumor DNA (ctDNA) is a novel tool in clinical oncology, however, its use has been limited in glioma to date, due to low levels of ctDNA. In this study, we aimed to demonstrate that sequencing techniques optimized for liquid biopsy in glioma patients can detect ctDNA in plasma with high sensitivity and with potential clinical utility. Methods: We investigated 10 glioma patients with tumor tissue available from at least 2 surgical operations, who had 49 longitudinally collected plasma samples available for analysis. Plasma samples were sequenced with CAPP-seq (AVENIO) and tissue samples with TSO500. Results: Glioma-derived ctDNA mutations were detected in 93.8% of plasma samples. 25% of all mutations detected were observed in plasma only. Mutations of the mismatch repair (MMR) genes MSH2 and MSH6 were the most frequent circulating gene alterations seen after temozolomide treatment and were frequently observed to appear in plasma prior to their appearance in tumor tissue at the time of surgery for recurrence. Conclusions: This pilot study suggests that plasma ctDNA in glioma is feasible and may provide sensitive and complementary information to tissue biopsy. Furthermore, plasma ctDNA detection of new MMR gene mutations not present in the initial tissue biopsy may provide an early indication of the development of chemotherapy resistance. Additional clinical validation in larger cohorts is needed.

2.
J Neuroimmunol ; 361: 577754, 2021 12 15.
Article in English | MEDLINE | ID: mdl-34700046

ABSTRACT

OBJECTIVES: To evaluate the ability for pre-treatment NLR and MLR to predict overall survival (OS) and modified Rankin Scale (mRS) and to explore their relationship with clinicopathological parameters. METHODS: Retrospective analysis of pretreatment NLR and MLR from 64 glioma patients. RESULTS: Higher pretreatment NLR (>4.7) predicted higher mean admission mRS (p < 0.001) and 6-month mRS (p = 0.02). Higher pretreatment MLR (>0.35) was a risk factor for poorer OS in glioma patients (p = 0.024). Higher pretreatment NLR was significantly associated with larger tumor diameter (p = 0.02). CONCLUSION: NLR and MLR can serve as prognostic markers to predict functional outcomes and OS in glioma patients.


Subject(s)
Brain Neoplasms/blood , Glioma/blood , Leukocyte Count , Monocytes , Neutrophils , Adult , Aged , Aged, 80 and over , Area Under Curve , Biomarkers , Brain Neoplasms/mortality , Female , Glioma/mortality , Humans , Kaplan-Meier Estimate , Lymphocyte Count , Male , Middle Aged , Prognosis , ROC Curve , Retrospective Studies , Young Adult
3.
J Neurooncol ; 154(3): 265-274, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34529228

ABSTRACT

PURPOSE: The leading cause of early death in patients with neurofibromatosis type 1 (NF1) is malignant peripheral nerve sheath tumor (MPNST). The principles of management include early diagnosis, surgical clearance and close monitoring for tumor recurrence. Current methods for diagnosis, detection of residual disease and monitoring tumor burden are inadequate, as clinical and radiological features are non-specific for malignancy in patients with multiple tumors and lack the sensitivity to identify early evidence of malignant transformation or tumor recurrence. Circulating tumor DNA (ctDNA) is a promising tool in cancer management and has the potential to improve the care of patients with NF1. In the following article we summarise the current understanding of the genomic landscape of MPNST, report on the previous literature of ctDNA in MPNST and outline the potential clinical applications for ctDNA in NF1 associated MPNST. Finally, we describe our prospective cohort study protocol investigating the utility of using ctDNA as an early diagnostic tool for MPNSTs in NF1 patients.


Subject(s)
Neurofibromatosis 1 , Neurofibrosarcoma , Circulating Tumor DNA/genetics , Humans , Neoplasm Recurrence, Local , Nerve Sheath Neoplasms/diagnosis , Nerve Sheath Neoplasms/genetics , Neurofibromatosis 1/complications , Neurofibromatosis 1/diagnosis , Neurofibromatosis 1/genetics , Neurofibrosarcoma/diagnostic imaging , Neurofibrosarcoma/etiology , Neurofibrosarcoma/genetics , Prospective Studies
4.
Purinergic Signal ; 16(3): 327-336, 2020 09.
Article in English | MEDLINE | ID: mdl-32583309

ABSTRACT

Gliomas, the most common primary brain cancer, are highly infiltrative and extremely difficult to treat. Despite advancements, current treatment is limited, with patients surviving for a median of 14-15 months post-diagnosis. Previous research has demonstrated the upregulation of a purinergic receptor, P2X7R, in human gliomas. P2X7R is expressed on both glioma cells and microglia within the glioma microenvironment. It is hypothesized that P2X7R contributes to tumour growth and proliferation via immune-mediated mechanisms involving tumour cells and surrounding microglia. We sought to elucidate the role of P2X7R in a human glioblastoma cell line (U251) and on surgically resected human glioma samples. We treated U251 and human glioma cultures for 72 h with P2X7R antagonists, Brilliant Blue G (BBG), oxidized ATP (oATP) and AZ10606120. Cell counting via fluorescence confocal microscopy was conducted to assess tumour proliferation. We observed no significant reductions in tumour cell numbers following P2X7R antagonism with BBG (20 µM) and oATP (250 µM) in both U251 cells and human glioma samples. Interestingly, there was a significant reduction in tumour cell number in both U251 cells (p = 0.0156) and human glioma samples (p = 0.0476) treated with varying concentrations of AZ10606120. When compared with the conventional chemotherapeutic agent, temozolomide, AZ10606120 was also found to more effectively inhibit tumour proliferation in U251 cells (p < 0.0001). Our pilot results demonstrate a potential trophic role of P2X7R where its inhibition by AZ10606120, a potent antagonist, hinders glioma growth directly or through the inactivation of microglia. This sheds new light on P2X7R as a therapeutic target for human gliomas.


Subject(s)
Brain Neoplasms/pathology , Cell Proliferation/drug effects , Glioma/pathology , Purinergic P2X Receptor Antagonists/therapeutic use , Adamantane/analogs & derivatives , Adamantane/pharmacology , Aminoquinolines/pharmacology , Brain Neoplasms/metabolism , Cell Line, Tumor , Glioma/metabolism , Humans , Microglia/drug effects , Microglia/metabolism , Microscopy, Confocal , Purinergic P2X Receptor Antagonists/pharmacology , Receptors, Purinergic P2X7/metabolism , Rosaniline Dyes/pharmacology , Signal Transduction/drug effects , Tumor Microenvironment/drug effects
5.
Neurology ; 79(9): 883-9, 2012 Aug 28.
Article in English | MEDLINE | ID: mdl-22843268

ABSTRACT

OBJECTIVE: To investigate the relationship of glutamate and glutamate transporter expression in human gliomas and surrounding peritumoral brain to the presence of tumor-associated seizures (TAS). METHODS: We studied a retrospective (group 1: 190 patients) and then a prospective (group 2: 98 patients) cohort of patients who underwent a craniotomy for a supratentorial glioma. Tumor and peritumor tissue specimens were assayed for glutamate concentration and expression of glial glutamate transporters. Differences between the seizure (TAS) and seizure-free (non-TAS) groups were compared. RESULTS: A total of 42% of patients had TAS, with 95% of seizures first occurring preoperatively. Clinical factors independently associated with risk of TAS were younger age, temporal lobe location, and tumors with oligodendroglial components. Molecular features in tumor specimens associated with TAS were higher glutamate concentrations, reduced EAAT2 expression, and increased system X(c)(-) expression. In group 2, these results were also replicated in the peritumor tissue. Logistic regression analysis identified raised glutamate concentrations in tumor and peritumor tissue, increased expression of peritumor system X(c)(-), younger age, temporal lobe location, and tumors with oligodendroglial components as independently predictive of preoperative seizures. CONCLUSION: Relative increased glutamate concentration in gliomas, and altered glutamate transporter expression, are associated with the presence of TAS and may play a mechanistic role in their pathogenesis.


Subject(s)
Glioma/complications , Glioma/genetics , Glutamic Acid/metabolism , Seizures/epidemiology , Seizures/etiology , Supratentorial Neoplasms/complications , Supratentorial Neoplasms/genetics , Vesicular Glutamate Transport Proteins/metabolism , Adult , Amino Acid Transport System y+/genetics , Astrocytoma/complications , Astrocytoma/genetics , Astrocytoma/metabolism , Blotting, Western , Cohort Studies , Excitatory Amino Acid Transporter 1/genetics , Excitatory Amino Acid Transporter 2 , Female , Glioblastoma/complications , Glioblastoma/genetics , Glioblastoma/metabolism , Glioma/metabolism , Glutamate Plasma Membrane Transport Proteins/genetics , Humans , Logistic Models , Male , Middle Aged , Odds Ratio , Retrospective Studies , Risk Factors , Supratentorial Neoplasms/metabolism , Vesicular Glutamate Transport Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...